Bausch Health Companies Inc. (NYSE:BHC) shares saw unusually-high trading volume on Tuesday . Approximately 146,533 shares were traded during mid-day trading, a decline of 96% from the previous session’s volume of 3,358,736 shares.The stock last traded at $28.04 and had previously closed at $26.11.
BHC has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Bausch Health Companies in a research note on Thursday, July 8th. Barclays cut their price objective on Bausch Health Companies from $35.00 to $31.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 4th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $32.64.
The firm has a market capitalization of $9.99 billion, a P/E ratio of -7.78, a P/E/G ratio of 0.55 and a beta of 1.71. The stock has a fifty day simple moving average of $28.20 and a two-hundred day simple moving average of $29.84. The company has a debt-to-equity ratio of 39.55, a current ratio of 0.99 and a quick ratio of 0.79.
In other Bausch Health Companies news, Director Schutter Richard U. De bought 10,000 shares of the stock in a transaction on Wednesday, August 4th. The stock was acquired at an average cost of $25.01 per share, for a total transaction of $250,100.00. Following the completion of the acquisition, the director now owns 317,109 shares in the company, valued at approximately $7,930,896.09. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 13.75% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in BHC. Atlas Capital Advisors LLC bought a new stake in shares of Bausch Health Companies during the first quarter valued at approximately $27,000. BDO Wealth Advisors LLC bought a new stake in shares of Bausch Health Companies during the first quarter valued at approximately $36,000. Heritage Wealth Advisors bought a new stake in shares of Bausch Health Companies during the second quarter valued at approximately $42,000. Tarbox Family Office Inc. bought a new stake in shares of Bausch Health Companies during the second quarter valued at approximately $59,000. Finally, Ameritas Investment Company LLC bought a new stake in shares of Bausch Health Companies during the first quarter valued at approximately $67,000. Hedge funds and other institutional investors own 70.31% of the company’s stock.
Bausch Health Companies Company Profile (NYSE:BHC)
Bausch Health Cos., Inc engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products.
Featured Article: Why do earnings reports matter?
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.